NCT06106672: Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis |
|
|
| Recruiting | 1/2 | 54 | US | CNP-106, Placebo | COUR Pharmaceutical Development Company, Inc. | Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG | 06/26 | 08/26 | | |
| Recruiting | N/A | 200 | US | | Disarm Therapeutics, Eli Lilly and Company | Chemotherapy-induced Peripheral Neuropathy | 03/24 | 04/24 | | |